There are 3161 resources available
752P - Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
Presenter: Tibor Zwimpfer
Session: Poster session 02
753P - Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial
Presenter: Felix Blanc-Durand
Session: Poster session 02
754P - Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Presenter: Ronnie Shapira-Frommer
Session: Poster session 02
755P - Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer
Presenter: Maj Kamille Kjeldsen
Session: Poster session 02
756P - Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
Presenter: Junsik Park
Session: Poster session 02
757P - Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study
Presenter: Juan Cueva Banuelos
Session: Poster session 02
758P - Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Presenter: Emese Zsiros
Session: Poster session 02
759P - JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies
Presenter: Qunxian Rao
Session: Poster session 02
760P - Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial
Presenter: Jie Tang
Session: Poster session 02
761P - Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies
Presenter: Bastian Czogalla
Session: Poster session 02